Genentech’s giredestrant (Wilserdly®), an oral SERD and estrogen receptor antagonist, has been FDA-approved in combination with the mTOR inhibitor everolimus for adults with ESR1-mutated, ER+/HER2− locally advanced or metastatic breast cancer.
Giredestrant is the fourth oral SERD to receive FDA approval, following Stemline’s elacestrant (Orserdu®), Lilly’s imlunestrant (Inluriyo®), and AstraZeneca’s camizestrant (Etcamah®).
The approval was supported by results from the Ph. 3 evERA trial. In patients with ESR1-mutated tumors, giredestrant plus everolimus reduced the risk of disease progression or death by 62% compared with standard endocrine therapy plus everolimus.
Genentech has also filed an NDA for giredestrant as adjuvant treatment for ER+/HER2− early-stage breast cancer. The FDA’s decision is expected by November 30.
Revisit our December 2025 case study to learn more about giredestrant’s discovery and development, along with the late-stage oral SERD competitive landscape.
Ascendis’ Weekly CNP Prodrug Navepegritide Gains FDA Approval for Achondroplasia | drughunters.com/3WJna3P
Ascendis Pharma’s navepegritide (Yuviwel®) has joined the growing list of targeted therapies for achondroplasia—and brings a notable dosing advantage: once-weekly administration.
The CNP prodrug uses Ascendis’ TransCon technology to overcome the notoriously short half-life of endogenous CNP, providing sustained exposure while counteracting the excessive FGFR3 signaling that drives achondroplasia.
In this Drug Hunter article, we explore: • The FGFR3 biology underlying achondroplasia • How CNP became a validated therapeutic strategy • The peptide and PEG optimization behind navepegritide • Clinical results supporting its FDA approval • Ascendis’ combination strategy with its human growth hormone prodrug, lonapegsomatropin • Emerging competition from oral FGFR inhibitors
See how peptide engineering turned a molecule with a half-life of only minutes into a once-weekly therapy. Read more on Drug Hunter: drughunters.com/3WJna3P
Novartis Discloses WIZ Degrader NVP-ITU512 for the Treatment of Sickle Cell Disease
Novartis’ James Manning disclosed the company’s CRBN-mediated molecular glue degrader of the WIZ transcription factor, NVP-ITU512 at the EFMC Medicinal Chemistry 2026 First Time Disclosures session in Basel, which detailed the team’s compromise between potency and a clean off-target profile for the treatment of a chronic illness in diverse patients with varied healthcare access.
From a phenotypic degradation screen in primary human erythroblasts derived from CD34+ cells, a medicinal chemistry optimization campaign focused on the development of two distinct series, with a premium placed on CRBN neosubstrate selectivity that led to prioritization of a novel CRBN-binding chemotype.
NVP-ITU512 demonstrates balanced potency and off-target profiles with desirable ADME properties, and the molecule progressed into clinical trials in 2024, where Novartis will likely attempt to position NVP-ITU512 as a universal oral therapy option for a globally diverse SCD patient population.
Bayer’s asundexian (Sunharbo®) has become the first factor XIa inhibitor to receive FDA approval. Approved in combination with antiplatelet therapy, it reduces stroke risk in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack.
In the Ph. 3 OCEANIC-STROKE trial, once-daily oral asundexian added to antiplatelet therapy reduced the relative risk of ischemic stroke by 26% compared with antiplatelet therapy alone. FXIa inhibitors have been a sought-after treatment option for secondary stroke prevention due to their potential to decouple therapeutic anticoagulation from increased bleeding risk, a common safety concern with DOACs (direct oral anticoagulants).
What did it take to discover and develop this first-in-class FXIa inhibitor? Revisit our April case study to explore asundexian’s discovery, development, and potential impact.